Figure 1.
NPM1-mutated myeloid sarcoma of the skin. (A) Dermal infiltration by leukemic cells (skin biopsy, B5-fixed; hematoxylin-eosin, original magnification ×400). (B) Leukemic cells exhibit aberrant cytoplasmic expression of NPM1 (arrow). Normal cells of epidermis show nucleus-restricted expression of NPM1 (double arrows) (immune alkaline phosphatase anti-alkaline phosphatase [APAAP] staining, original magnification ×400). (C) Leukemic cells in the derma are myeloperoxidase-positive (APAAP staining, original magnification ×400). Ep, epidermis. (D-E) Cutaneous nodules at diagnosis (D) disappeared after induction chemotherapy (E). (F) Monitoring of NPM1mut transcripts during therapy and follow-up (see text). 0.0001 is equivalent to MRD negativity. ActD, dactinomycin; Rel, relapse; RQ-PCR, RT-qPCR.

NPM1-mutated myeloid sarcoma of the skin. (A) Dermal infiltration by leukemic cells (skin biopsy, B5-fixed; hematoxylin-eosin, original magnification ×400). (B) Leukemic cells exhibit aberrant cytoplasmic expression of NPM1 (arrow). Normal cells of epidermis show nucleus-restricted expression of NPM1 (double arrows) (immune alkaline phosphatase anti-alkaline phosphatase [APAAP] staining, original magnification ×400). (C) Leukemic cells in the derma are myeloperoxidase-positive (APAAP staining, original magnification ×400). Ep, epidermis. (D-E) Cutaneous nodules at diagnosis (D) disappeared after induction chemotherapy (E). (F) Monitoring of NPM1mut transcripts during therapy and follow-up (see text). 0.0001 is equivalent to MRD negativity. ActD, dactinomycin; Rel, relapse; RQ-PCR, RT-qPCR.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal